**Author details**

Hulya Bukulmez\* and Gurinder Kumar Department of Pediatrics, Division of Pediatric Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA

\*Address all correspondence to: hxb38@case.edu

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**149**

*Clinical Use of Mesenchymal Stem Cells in Treatment of Systemic Lupus Erythematosus*

[9] Tanaka Y, O'Neill S, Li M, et al. Systemic Lupus Erythematosus: Targeted literature review of the epidemiology, current treatment and disease burden in the Asia Pacific region. *Arthritis Care Res (Hoboken)* 2020 2020/08/26. DOI: 10.1002/

[10] McCormick N, Marra CA, Sadatsafavi M, et al. Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study. *Semin Arthritis Rheum* 2020; 50: 77-83.

2019/07/31. DOI: 10.1016/j. semarthrit.2019.06.010.

[11] Bezalel S, Guri KM, Elbirt D, et al. Type I interferon signature in systemic lupus erythematosus. *Isr Med Assoc J* 2014; 16: 246-249. 2014/05/20.

[12] Dema B and Charles N. Advances in

[13] Torell F, Eketjall S, Idborg H, et al. Cytokine Profiles in Autoantibody Defined Subgroups of Systemic Lupus Erythematosus. *J Proteome Res* 2019; 18: 1208-1217. 2019/02/12. DOI: 10.1021/acs.

[14] Hayashi T. Therapeutic strategies for SLE involving cytokines: mechanismoriented therapies especially IFNgamma targeting gene therapy. *J Biomed Biotechnol* 2010; 2010 2010/09/10. DOI:

[15] O'Neill S and Cervera R. Systemic lupus erythematosus. *Best Pract Res Clin* 

Figueiredo MA, et al. Interrelationship

*Rheumatol* 2010; 24: 841-855. 2011/06/15. DOI: 10.1016/j.

[16] Trucci VM, Salum FG,

mechanisms of systemic lupus erythematosus. *Discov Med* 2014; 17:

247-255. 2014/06/03.

jproteome.8b00811.

10.1155/2010/461641.

berh.2010.10.006.

acr.24431.

*DOI: http://dx.doi.org/10.5772/intechopen.97261*

Moutsopoulos HM. Sjogren's syndrome: Old and new therapeutic targets. *J Autoimmun* 2020; 110: 102364. 2019/12/14. DOI: 10.1016/j.jaut.

[3] Ball LM, Egeler RM and Party EPW.

[4] Bawazier LA. Current and Emerging Therapy on Lupus Nephritis. *Acta Med Indones* 2017; 49: 369-377. 2018/01/20.

Savarimuthu I, et al. Current Trends in the Treatment of Systemic Lupus Erythematosus. *Curr Pharm Des* 2020; 26: 2602-2609. 2020/02/19. DOI: 10.2174/

[6] Hanly JG, Kozora E, Beyea SD, et al. Review: Nervous System Disease in Systemic Lupus Erythematosus: Current Status and Future Directions. *Arthritis Rheumatol* 2019; 71: 33-42. 2018/06/22.

[7] Adam Z, Sokwala A, Shah J, et al. A

thrombocytopenia purpura occurring in systemic lupus erythematous. *Pan Afr Med J* 2019; 34: 103. 2020/01/15. DOI: 10.11604/pamj.2019.34.103.20524.

[8] Safiri S, Kolahi AA, Cross M, et al. Global, regional, and national burden of other musculoskeletal disorders 1990- 2017: results from the Global Burden of Disease Study 2017. *Rheumatology (Oxford)* 2020 2020/08/26. DOI: 10.1093/rheumatology/keaa315.

delay in diagnosis: thrombotic

Acute GvHD: pathogenesis and classification. *Bone Marrow Transplant* 2008; 41 Suppl 2: S58-64. 2008/07/24.

DOI: 10.1038/bmt.2008.56.

[5] Raja TW, Veeramuthu D,

1381612826666200211122633.

DOI: 10.1002/art.40591.

[1] Maroz N and Segal MS. Lupus nephritis and end-stage kidney disease. *Am J Med Sci* 2013; 346: 319-323. 2013/02/02. DOI: 10.1097/MAJ.

0b013e31827f4ee3.

**References**

2019.102364.

[2] Mavragani CP and

*Clinical Use of Mesenchymal Stem Cells in Treatment of Systemic Lupus Erythematosus DOI: http://dx.doi.org/10.5772/intechopen.97261*
